First patients dosed in new cancer drug trial
NCT ID NCT07334119
Summary
This is the first study in people to test a new drug called MT-304 for adults with advanced cancers that have a protein called HER2. The main goals are to check the safety of the drug, find the best dose, and see if it shows any early signs of helping to control the cancer. Participants will receive MT-304 by itself or combined with another cancer drug, nivolumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, 2298, Australia
Contact
Contact Phone: •••-•••-••••
-
Cancer Research SA Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-••••
Contact
-
Icon Cancer Centre South Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-••••
Contact
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-••••
Contact
-
Scientia Clinical Research Ltd
RECRUITINGRandwick, New South Wales, 2031, Australia
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.